Meet our mentors

OneStart 2016 mentors are experts across various fields, from experienced entrepreneurs, to venture capitalists and representatives of the world's leading pharma companies, to experts on IP and corporate law (see below).

There are 35 semi-finalist teams for each strand of the programme (Europe and Americas) for 70 semi-finalist teams in total. Each team will be paired up with one or two mentors in January to March 2016. The mentor(s) will spend 30-60 minutes each week with the team to provide advice and guidance until the end of the program.

Would you like to mentor a OneStart semi-finalist startup from mid-January to mid-March 2016?

Please tell us about your experience and interests via the Full Registration Form, or quickly leave your contact details below if you'd like us to get in touch directly with more information.

Americas Mentors
Jens Eckstein
President, SR One + more
I came to SR One from TVM Capital where I was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, I was a General Partner in TVMs Boston life sciences practice where I focused on earlier-stage investments. I am currently Chairman of the Board of Directors of Thrasos Therapeutics and a Director at Alios BioSciences. I was also the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company.
Art Bertelsen
Vice President, Bristol-Myers Squibb, Princeton, New Jersey + more
Vice President Research Collaborations at Bristol-Myers Squibb, Princeton, New Jersey
Ilan Zipkin
Senior Investment Director at Takeda Ventures, Inc. + more
I have been involved in biotechnology and pharmaceutical venture capital since 2000. Previously I was a Partner at the institutional venture firms Prospect Venture Partners and MPM Capital, where I focused on investments in therapeutics companies as well as platform technologies. In addition to serving on the Board of several private and public biotechnology companies, I served as the CEO of Chimeros, Inc., a protein-based system for the development of multivalent biologic therapeutics.
Paul Jansen
Global Head Medical Devices at Sanofi-Aventis + more
Strong drug/ biologics device development experience (registration, CMC, manufacturing, quality, business development). Demonstrated success in cross cultural work environments (Japan and EU) and excellent project management skills. Demonstrated ability to think strategically, creatively and tactically ensuring that thoughtful plans translate into coordinated action. Strong leader, having developed and led through many difficult situations. Excellent relationship skills. Highly respected by peers. Gets results through people (internally and from alliances).
Kimberly Raia
Associate Director at Boehringer Ingelheim + more
Associate Director, Business Model and Healthcare Innovation at Boehringer Ingelheim
Thomas Luby
Senior Director, New Ventures, Johnson & Johnson Innovation, Boston + more
I focus primarily on cardiovascular & metabolic; infectious diseases and vaccines; and neurobiology. Prior to joining Johnson & Johnson, I was Senior Director of Research Ventures at Shire Human Genetic Therapies.
David Wilson
VP Biologics Research at Teva Pharmaceuticals + more
Specialties: Biologics, therapeutic antibodies, target validation, cancer, protein engineering, combinatorial biology, structural biology, biochemistry, business development
Vijayalakshmi Agnani
Head of Office, External Innovation Operations | Strategy, Science Policy and External Innovation at Sanofi + more
Vijayalaksmi (Viju) Agnani joined Sanofi as Head of Office, External Operations in Feb 2015.She joined Sanofi after an 8 year career in the research division at Merck and Co. Most recently, Viju was Manager, Strategic Operations where she managed a number of external research alliances at Merck Research Labs, which included working with biotechnology companies, CROs and premier academic institutions around the world. As Partner Relationship Manager she led all day-to-day operational and tactical aspects of the partnerships. While in this role, she spearheaded the launch of the Merck Innovation Network initiative, a first of its kind Open Innovation effort at Merck. Prior to that, she was a biologist at the Cardiovascular Diseases and In Vitro Pharmacology groups at Merck where she led biochemistry and biophysics research supporting Merck’s Cardiovascular portfolio.
Cayce Denton
Vice President, TPG Biotech + more
Prior to joining TPG Biotech in 2010, I managed finance for the Nutropin and Lytics franchises at Genentech, Inc., where I also participated in a CFO Rotation Program consisting of time in R&D Finance, Financial Planning and Analysis, Audit and Treasury. Prior to Genentech, Inc., I was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, Inc.
Timur Gungor
Principal Scientist and Alliance Manager at Bristol-Myers Squibb + more
Principal Scientist and Alliance Manager at Bristol-Myers Squibb
Sutanto Widjaja
Portfolio Manager, Symphony Asset Management + more
I have over 10 years of Healthcare Investment experience and I'm a Co-Founder of Sutro Biopharma (funded by SV Life Sciences, Alta Partners, Skyline Ventures, Amgen Ventures, Lilly Ventures and Celgene) and Manager at (funded by Kleiner).
Jill Carroll
Senior Associate, SR One + more
I joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, I was responsible for Corporate Development at Dynavax Technologies, where I was involved in multiple pharma partnering deals as well as substantial private and public financings. Previously, I was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting.
Marie Leithauser
Executive Director, Business Operations, Research at Bristol-Myers Squibb + more
Marie Leithauser holds the position of Executive Director of Business Operations for Bristol-Myers Squibb's Research organization. She has served on the New Jersey Commission on Cancer Research and as a member of the State Theater's Education Committee. Experience at Bristol-Myers Squibb: * Chief of Staff for Senior Vice President, Research * Focus Senior Team on high impact business issues and drive related strategy development * String of Pearls integration planning * Process simplification
Simeon J. George
Partner, SR One + more
I lead SR One's investment activities on the West Coast. Prior to joining SR One, I was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.
Kobi Cohen
Director, Search & Evaluation, Global R&D at Teva Pharmaceutical Industries Ltd. + more
Business development oriented complemented by strong and wide scientific experience in Oncology, Neurology, Pain and Autoimmune/ inflammatory diseases. Highly experienced in preclinical development and scientific evaluation of preclinical and clinical data.
Vikas Goyal
Associate, SR One + more
I joined SR One in January 2011, after interning with SR One since 2009. Prior to joining SR One, I was a consultant at McKinsey & Co, a co-founder of Extera Partners, and a business development manager at Infinity Pharmaceuticals. Over my career, I have supported business and corporate development activities for nearly 50 large and small public, venture-backed, and angel funded life science companies.
Ken Colley
Medical Director, Translational and Integrative Medicine at BioVasc Inc. + more
Dr. Kenneth J. Colley, MD, PhD, is an accomplished physician-­‐scientist-­‐entrepreneur with  two  decades  experience  in  clinical  medicine,  pharmaceutical  product  development,  the biotech/medtech/nutratech industries, and startups formation and funding. Ken is currently  and  since  2012  a  consulting  Medical  Director  at  Theravance  BioPharma,  a publically-­‐traded biopharma company (TBPH), and most recently from 2009-­‐2011 was Medical Director at diaDexus Inc., a publically-­‐traded cardiovascular biotech company, also based in South San Francisco. Prior to that he was VP Product Development at Medlogics Device  Corporation,  a  cardiovascular  pharma-­‐medtech  firm  focused  on  interventional  cardiology and next generation DES, where he was responsible for pharmaceutical R&D, preclinical and clinical aspects of Medlogics' product development. He joined Medlogics in 2004 as the lead Science and Technology officer concurrent with its deal acquiring certain assets  of  BioVasc  Inc.,  an  emerging  medtech/biotech  company  developing  cardiovascular  products at the convergence of biopharmaceuticals and medical devices, which he founded in 2003. Prior to that Ken served as VP Product Development for start-­‐up orthobiologics company OsteoGenix Inc. (acquired by Medtronic orthobiologics unit), while serving on the development team at Shalon Ventures in Palo Alto. Dr. Colley was formerly the founding CEO and medical and technology director of Angiogenix Inc., raising over $20 million from start-­‐up in 1998 through early clinical trial phases prior to his departure to form BioVasc in 2003. Prior to Angiogenix, Dr. Colley designed advanced drug delivery systems at Cygnus Inc.   He  received  his  M.D.  from  Georgetown  University,  subsequently  training  in  Internal  Medicine at Johns Hopkins University, and also received his Ph.D. in Molecular Pharmacology  from  Georgetown  University.   He  holds  a  B.S.  in  Biological  Sciences  with  a  product design engineering minor from Stanford University.
Simon Greenwood
Genentech Investment Director, Roche Venture Fund + more
I am an investment director for the Roche Venture Fund with more than 15 years of experience in the biotechnology industry. In this role, I have led investments in companies such as Allakos, Biodesy, CytomX, DVS (acquired by Fluidigm), Epic Sciences, Maculogix and Stratos. Prior to his role at the Roche Venture Fund, I was the head of GenenFund, Genentech’s corporate venture fund.
Jaione Maiz
Analytics Valuations Associate, Life Science Specialist, Silicon Valley Bank + more
I joined Silicon Valley Bank in 2013, after an internship at venBio. This is my second year of being involved in OneStart.
Samuel Wu
Managing Director at MedImmune Ventures + more
Samuel Wu joined MedImmune Ventures in 2010. He is or has been a board member of Applied Genetic Technologies Corp (NASDAQ:AGTC), Cerapedics, and VaxInnate. Previously he was a principal with SV Life Sciences, a healthcare-focused venture capital firm he had joined in 2002, where he invested in a broad range of biopharmaceutical, platform and medical device companies. Before moving into venture capital, he was an Engagement Manager in the Pharmaceuticals and Corporate Finance practices of McKinsey and Company, where he led teams of consultants serving clients on M&A, portfolio analysis and other strategic issues.
Stefan Engst
Principal Scientist, Cytokinetics + more
I am a Principal Scientist with extensive multidisciplinary experience in drug discovery and candidate selection. I have advised executive management and key senior staff, establishing scientific guidance and ongoing strategic planning for oncology, metabolic and muscular disease projects.
Danny Janiak
Partner, Mercury Fund + more
I focus on new company creation and early-stage investment opportunities in the life sciences. Prior to joining Mercury, I was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community.
Douglas Crawford
Associate Director, QB3 & Managing Director, Mission Bay Capital + more
My goal is to help entrepreneurial scientists create successful startups to meet California’s needs for better health, a sustainable environment, and economic growth—particularly jobs. To this end, my colleagues at QB3 and I have systematically lowered the barriers between great ideas and successful companies. I am also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage venture fund that makes pivotal early-stage investments in bioscience companies.
Caleb Bell
Founder & CEO, Bell Biosystems + more
I am the Founder and CEO of Bell Biosystems, a synthetic biology company developing living biological tools from a proprietary process that add complex function to cells. I founded Bell BioSystems during my PhD in Biophysical Chemistry at Stanford University.
Ting Jia
Biotech Analyst, BVF Partners + more
I am a biotech analyst at BVF Partners, a private equity firm, looking to invest in all areas of biotechnology sector. Before I was an Engagement Manager at McKinsey & Company for 3 years, specializing in Pharmaceuticals and Medical Products and Private Equity & Principal Investors.
Ben Wang
Founder of Svaya Nanotechnologies, Inc. + more
I founded Svaya ( Common to the unique. Bad ass surface engineering. I am also a managing partner of 26.2 Ventures LLC where we focus on commercializing technologies for applications in the energy, water, health, and developing nations arenas.
David Spellmeyer
Chief Technology Officer, Nodality + more
I joined Nodality in 2006. Prior to Nodality, I held positions as a research staff member in the IBM Almaden Services Research group, as chief scientific officer and vice president of drug discovery at Signature BioSciences, as executive director at DuPont Pharmaceuticals, as vice president at CombiChem, and a principal scientist at Chiron.
Justin Chakma
Associate, Thomas, McNerney & Partners + more
I joined Thomas, McNerney & Partners in 2012, having previously conducted research in support of the Bill and Melinda Gates Foundation. I am a venture capitalist with a focus on building life sciences start-ups. I have experience in investment banking, business development and government innovation policy.
Colleen Cutcliffe
Co-founder & CEO, Whole Biome + more
I am a co-founder and CEO of Whole Biome, a company working with the Mayo Clinic and others to analyze the microbiome, and to develop therapies that use the microbiome to improve human health. Whole Biome, which has been in operation for one year, is a resident company in the Janssen Labs @QB3 space at QB3@953.
Nick Antoniadis
Commercialization Consultant + more
I am a senior strategic marketing leader with 20 years of healthcare experience who delivered on complex global product launches. I have produced award winning strategies that maximize the opportunity at hand with tactics that have been adopted by regional markets around the world.
Ravi Kaiwar
Business Development Consultant + more
I have over 20 years of experience in the biopharmaceutical industry with extensive business development, commercial, drug development and R&D experience.
Rick Beberman
Digital Health/Health IT Investment and Corporate Development Professional + more
I have an extensive background in health information technology and digital health. I am currently a member of the advisory board of Trinity Health, an early stage company that has developed a virtual meeting room to assist multidisciplinary medical teams that deliver more effective team-based care. For four year I was a venture associate with Health Care Investment Visions, an organization that invests in seed stage health information tech companies and led business development for one of its portfolio companies. For 15 years, he was an investment banker with No America affiliate of NM Rothschild & Sons and later with Banc of America Securities advising clients on mergers, acquistins, partnerships, and capital raising. He has an MBA from NYU and masters in accounting from USC.
Steven Robinette
Associate, McKinsey & Company + more
Steven Robinette is an associate at Atlas and joined in 2015. Previously, Steven was an engagement manager at McKinsey & Company, serving pharmaceutical and biotechnology clients on R&D topics. These topics included R&D investment strategies for a global pharmaceutical company, a platform biotechnology company, and an oncology business unit; single asset diligences in immunology, oncology, and CNS/pain; and post-acquisition integration of R&D organizations.
James Mutamba
Senior Associate at PureTech + more
Dr. Mutamba is a Senior Associate at PureTech, and is part of the company creation team, focusing on opportunities in the microbiome, epigenetics and metabolic diseases. Prior to joining PureTech, Dr. Mutamba was a strategy consultant at ClearView Healthcare Partners and played multiple roles in research and product development at Pathogenica, Inc., a biotech start up. Dr. Mutamba completed his graduate work at MIT in the Department of Biological Engineering, focusing on the relationship between inflammation-derived reactive species and cancer. During his graduate work, Dr. Mutamba received a Medtronic Graduate Fellowship and several Environmental Mutagen Society awards. He also completed coursework at the MIT Sloan School of Management. Dr. Mutamba received his B.S. in Biochemistry from UNCG, and his Ph.D. from MIT.
Nick Conley
CEO & Cofounder of EpiBiome + more
Dr. Nick Conley is Chief Executive Officer and Cofounder of EpiBiome, an eleven-person, venture-backed precision microbiome engineering company based in South San Francisco, California. He completed a PhD in Chemistry and a postdoctoral fellowship in Developmental Biology at Stanford University, where he trained as a synthetic chemist and molecular biologist. Dr. Conley possess direct Nobel Laureate pedigree, having worked at Stanford University with Prof. W. E. Moerner, winner of the 2014 Nobel Prize in Chemistry. Dr. Conley was a Beckman Fellow, a National Science Foundation Graduate Research Fellow, a Lieberman Fellow, a Stanford Molecular Imaging Scholars Fellow, and a Younger Fellow. He has published 18 peer-reviewed journal articles on topics including palladium catalysis, super-resolution fluorescence imaging, single-molecule DNA detection, and cancer biology, and he holds 4 US patents. Prior to cofounding EpiBiome, Dr. Conley was a Research Staff Member at HGST, a Western Digital Company. He has also cofounded several successful companies in the oral and skincare space. During his free time, he enjoys competing in triathlons and spending time with his basset hound.
Neil Littman
Business Development, California Institute for Regenerative Medicine + more
The California Institute for Regenerative Medicine (CIRM) was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research, was overwhelmingly approved by voters and called for the establishment of an entity to provide funding for stem cell research in California. Business development responsibilities include establishing and maintaining relationships with current and prospective partners, including: companies, academic institutions, international agencies, disease foundations, and investors. I actively pursue potential partners and licensees for CIRM’s portfolio of >70 active therapeutic programs. I proactively identify and screen external stem cell programs for inclusion in CIRM’s $3 billion portfolio. I also help manage international partnerships and other collaborations including CIRM’s iPSC Bank and the Alpha Clinical Network. In addition, I am responsible for conducting competitive intelligence, financial modeling and forecasting, and valuation analyses. I am a frequently invited speaker and panelist at scientific and business development conferences.
Jamil Beg
Brand Marketing Director, Status Epilepticus Franchise + more
I have a dual science and business background. I worked in life science venture capital for several years before joining early stage startups in business development, strategy, and commercialization roles. I've been at SAGE Therapeutics since the Series A financing. I have worked across fund raising, BD (in-licensing IP to launch our programs) and have helped shepherd the programs through preclinical and clinical development. I am now leading the brand strategy team to prepare for the launch of the product (currently in Phase 3 development).
Ken Horne
CEO, Symic Bio + more
Mr. Horne has over 12 years of experience in the life science industry as an executive, entrepreneur and investor. He joined Symic Biomedical as CEO in April 2014. Previously, he was a founding member of TauTona Group, an early stage life science venture capital fund. At TauTona, Mr. Horne founded Aline Aesthetics, a novel biomaterial company, where he led the company as General Manager until its acquisition by Allergan (AGN) in 2014. He also served as Vice President of Business Development for TauTona portfolio companies, which included acquisitions by LifeCell and Novadaq (NVDQ). Mr. Horne has a BS and MS degree from Stanford University in mechanical engineering. He serves on the board of the Bay Area Discovery Museum (non-profit), and is also a Kauffman Fellow.
Doug Fisher
Executive-in-Residence at InterWest Partners + more
Doug joined InterWest's healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments, and portfolio company support. He is a board member of Gynesonics, Indi Molecular, Obalon Therapeutics, and QuatRx. Doug is also actively involved in InterWest's investments in Benvenue, Integrated Diagnostics, PMV Pharma, Potenza Theraputics, and Sera Prognostics (where he serves as the Chief Business Officer). Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group. Doug received an A.B. in economics with honors and distinction, and a B.S. in biology with distinction, from Stanford, where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton, where he graduated with honors as a Siebel Scholar and Palmer Scholar.
Ajay Rai
Independent Advisor + more
Over 20 years of experience in corporate finance, M&A, strategy and business development roles in banking and health care companies, including Ernst & Young, Roche Diagnostics, Forest Labs and Biogen. Most recently (through October 2015) was Senior Director of Business Development and M&A at Biogen, leading the Immunology, Pain and Fibrosis Business Development efforts.
Erik Gentalen
CEO + more
I have spent my career developing successful bioanalytical platforms at early stage startups like ProteinSimple, Caliper and Affymetrix. Recently founded Intabio, Inc. to help fill a desperate need in biopharmaceutical analysis. Background in manufacturing, corporate and business development, R&D and intellectual property.
Cathy Tralau-Stewart
Associate Director Catalyst - Therapeutics + more
I am a drug discovery pharmacologist with extensive experience of progressing projects from Target Validation through to Clinical Proof of Concept. I worked for GlaxoSmithKline for nearly 20 years and as Associate Director pre-clinical pharmacology (Respiratory, Inflammation) was responsible for the lead optimization of over 20 programs and the discovery of over 10 candidate & marketed drugs. I founded and led the Imperial College London Drug Discovery Centre and 2 start-up companies, one with a compound currently progressing to Phase I for multiple myeloma. I currently run a translational therapeutics scheme at UCSF (Catalyst) supporting the progression of academic projects.
Adam Galan
Principal of synthetic organic and medicinal chemistry at Galan Consulting + more
Experienced medicinal/synthetic organic chemist; drug discovery scientist and project manager An experienced, enthusiastic, resourceful and versatile medicinal/synthetic organic chemist/project manager with proven scientific, laboratory and project management skills in the areas of early stage small molecule drug discovery/preclinical research to IND. Possesses a diverse scientific background which includes medicinal chemistry (screening libraries, lead validation, lead optimization, SAR, ADME, PKPD and pharmacology) and synthetic organic chemistry (target based synthesis, parallel synthesis, synthetic methodology development, process research & development, pre-IND scale-up and early stage CMC). Operational experience in staff mentoring, team and project management, company infrastructure (real and virtual mode), collaborations and global outsourcing. An accomplished goal-oriented collaborative problem solver with excellent interpersonal skills and a high level of familiarity with a wide range of software and informatics applications. Specialities: Drug discovery-development chemistry - early stage drug discovery and CMC to IND. Medicinal chemistry, Kinase inhibitors. Lead validation, hit to lead, lead change, lead optimization; Synthetic organic chemistry - method development, early stage process development and scale-up; early stage CMC.. Project management - medicinal and organic chemistry, preclinical scale up, formulation, ADME studies & in-vitro biology. Global outsourcing - management of projects, CROs and vendors for client and internal use; Global sourcing - raw materials, reagents, advanced intermediates, reference compounds & screening libraries; Global shipping of chemicals; Small-molecule solution phase parallel synthesis; library design Experienced cheminformatics user.
Adam McNulty
Scientific Partnering and Alliances, AstraZeneca + more
Scientific Partnering and Alliances supporting the Oncology iMED and the Emerging Innovations Unit (EIU), a virtualized, externally focused R&D team. This includes negotiation and execution of any and all agreements related to early stage small molecule oncology assets and the out licensing of phase 2b ready EIU assets.
Alexander Honkala
CEO, Ligandal + more
Ligandal (LNT) is engaged in the research and development of proprietary and customized therapeutic nanotechnology gene editing on top of a revolutionary scientific collaboration and knowledge management platform.
Andrew Maleki
Senior Analyst, PureTech Health + more
Previous experience include proving counsel to executives in the life sciences on a broad range of growth strategy issues, including asset and franchise strategy, marketing strategy, market entry (e.g., into new disease or therapeutic areas) strategy, and overall business unit/corporate growth strategy.
Arunan Skandar
Associate, McKinsey & Company + more
Experience: • Portfolio strategy and R&D innovation for a small biotech • Due diligence in medical products • Analysis of large survey data sets to understand how healthcare is utilized • Policy and innovation strategy in oncology • Mapping the journey for mental health services • Growth strategy in medical devices
Darshana Zaveri
Partner, Catalyst Health Ventures + more
Partner and member of Catalyst’s investment committee. Actively involved in all aspects of Fund Management including Investments and Capital Raising. Led Catalyst’s investments in Aria CV, Maxwell Health, Augmenix, Lantos Technologies, nVision Medical and Hepregen. Actively involved in portfolio company Allegro Diagnostics.
Dorothy Lou Bailey
Entrepreneur & Consultant + more
Creative, insightful, and high energy executive with a passion for innovation and a history of successfully leading teams and building partnerships within the life sciences industry.
Evan Anderson
CEO, Luma Therapeutics + more
CEO, Luma Therapeutics. Leading the development of a new home therapy for treating skin conditions. Specialties: clinical need identification, market assessment, acute animal studies, chronic animal studies, rapid prototyping, project management (MS Project), product development, medical research, product pipeline development, resource management
Duncan Young
Academic Alliances Manager, Scientific Partnering & Alliances, AstraZeneca + more
Experienced Business Development professional with keen interest in new models of collaborative working and open innovation between academia, the charity sector and industry. Specialities: Open Innovation, Drug Discovery, Medical Technologies, Technology Transfer, IP Management, Technical Due Diligence and Evaluation, Networking, Agreement Negotiation, Consortia Drafting
Jake Bauer
Vice President, Business Development & Business Operations, MyoKardia, Inc. + more
Jake Bauer has significant experience in the biopharmaceutical industry, bringing senior leadership experience, business development and business operations expertise to the company. He joined MyoKardia from Ablexis, LLC, where he was vice president, business operations and head of corporate development. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Ablexis’ AlivaMab Mouse Platform is licensed to six of the 20 global pharmaceutical companies. Prior to Ablexis Mr. Bauer was a principal at Third Rock Ventures, where he identified, evaluated and developed new opportunities for investment, assisted with startup, corporate development and operations of portfolio companies, and negotiated financings. He was actively involved in a variety of leading biopharmaceutical companies including Agios, CytomX, Global Blood Therapeutics and Zafgen. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals, and was previously a management consultant at Putnam Associates.
Jean-Marie Vallet
Life Sciences Entrepreneur & Investor + more
International experience (US, Germany, Switzerland, France) in large and small companies. Over 30 years of experience in the pharma/biotech industry acquired across several functional areas including, Research, Business Development/Licensing, Strategic Planning, Corporate M&A, Finance & Administration and International Sales. Specialties: Strategic analysis all the way from technology evaluation to commercial/marketing analysis to a negotiated, signed deal. Expertise in several functional areas including technology evaluation and research, financial modeling (M&A, transaction, business planning), strategic planning and analysis, equity investment, business development (screening, evaluation, financial, modeling, deal structuring), Operational Sales & Marketing (P&L responsability). Staff management.
Jessica Alston
Associate, F-Prime Capital Partners + more
Jessica focuses primarily on the biopharmaceutical and medical technology sectors. Prior to joining F-Prime in 2015, Jessica was an engagement manager in McKinsey and Company’s Boston office, where she focused on pharmaceuticals and medical products and advised companies across a range of strategic, organizational, and operational topics. She began her career at MIT Lincoln Laboratory in the Biodefense Systems group, where she worked on developing novel techniques for the detection of biological agents. Jessica holds a Ph.D. in genetics from Harvard University and received her BS in biology from Duke University, graduating summa cum laude.
Jill Jacobson
Partner, FisherBroyles, LLP + more
Jill Jacobson is a partner of FisherBroyles, LLP, The Next Generation Law Firm®. Attorney specializing in intellectual property law, with expertise in biotechnology, life sciences, chemistry, and chemical engineering technical fields. Practice focuses on patent procurement, patent portfolio evaluation, and strategic intellectual property counseling. Ph.D. in Biochemistry, with further technical background in chemistry and chemical engineering. J.D. degree, with 14+ years of experience as a patent practitioner. Member of California Bar and USPTO Patent Bar. Specialties -patent application drafting -patent prosecution -patentability searching -freedom to operate analysis -due diligence -evaluation of design around options -trademark registrations
Juan-Pablo Mas
Partner,Action Potential Venture Capital - GSK's Bioelectronic Medicines Innovation Fund + more
Juan-Pablo is an experienced operator, investor, electrical engineer, and medical technology enthusiast. He is focused on bioelectronics, the next generation of nueromodulating medical devices. As a Partner at Action Potential Ventures (GSK's bioelectronics venture fund), Juan-Pablo invests in the companies and technologies that enable the future of targeted and adaptive bioelectronic devices. Additionally, Juan-Pablo is passionate about the future of mobile health technology that can deliver measurable impact to behavior change, health outcomes, and health economics (both by consumer and clinical standards). He is a believer that design and context drive engagement, that data must provide users a perpetual benefit, and that experiences must be pleasurable and habit forming to be adopted and remain relevant in a health context.
Karl Handelsman
Founder, Codon Capital + more
In collaboration with scientific founders and entrepreneurs Karl fosters early stage life science innovation. He focuses on early stage pre-clinical therapeutic companies and synthetic biology. The startup search by entrepreneurs and the biotech industry to translate science into products is an evolving practice. In addition to working with science research organizations, such as UCSF and NIH, on translational programs he also makes angel investments in seed and series A startups. There are already examples where entrepreneurs were able to generate exits in under 18 months. Specialties: Biotech, early stage, company formation.
Kenneth Maynard
Portfolio Strategy and Externalization, CNS Therapeutic Area Unit, Takeda Pharmaceuticals + more
Recent past leadership roles include Chair, Membership and Communications Committee and held advocacy discussions with 2 members of the US Congress and was a recent participant in the White House Community Leaders Briefing on Cardiovascular Health for the American Heart Association/American Stroke Association’s Stroke Council. Recently served as a member of the Society for Neuroscience’s Finance Committee and currently serve on the Executive Committee of the International Dose-Response Society. Specialties: Subject matter expertise in neuroscience, especially cerebrovascular pathophysiology, specifically stroke.
Kevin Pojasek
President & CEO at Quartet Medicine + more
President and Chief Executive Officer of Quartet Medicine, a Cambridge, MA-based start-up discovering and developing novel treatments for chronic pain and inflammation. Dr. Pojasek co-founded Quartet in late 2013 as an entrepreneur-in-residence at Atlas Venture. Dr. Pojasek was also the Chief Operating Officer of Annovation Biopharma, a clinical-stage company developing novel intravenous anesthetics, which was sold to the Medicines Company in January 2105. Prior to joining Atlas in January 2013, Dr. Pojasek was Vice President of Corporate Development at Kala Pharmaceuticals, a developer of novel ophthalmology therapies, where he was responsible for the company’s corporate strategy, financing, board management, day-to-day operations, and business development activities. Dr. Pojasek joined Kala from Satori Pharmaceuticals where he oversaw the company’s development activities for the lead Alzheimer’s disease program. Prior to Satori, Dr. Pojasek co-founded and was the Executive Director of Development at Solace Pharmaceuticals where he oversaw the clinical development of the company’s lead compound, including the execution of a global Phase 2 neuropathic pain study. Dr. Pojasek also spent time at PureTech Ventures, an early stage venture capital firm, where he led the formation and management of several life science companies. Dr. Pojasek received his PhD from the Biological Engineering Department at MIT and his BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.
Linda K Molnar
Co-founder and CEO at Simpatica Medicine, Inc. + more
I am an experienced life sciences industry executive and scientist, and a champion of precision medicine. I bring a unique combination of technical and business acumen gained from experience in start-up, government, and business environments. My experience spans the scientific, business, regulatory and reimbursement issues in clinical translation. I have founded, funded and led several successful biotech start-up companies. I am particularly passionate about the application of advanced technologies to unmet needs in medicine.
Lou Tartaglia
Executive-In-Residence + more
Lou Tartaglia, Ph.D. joined 5AM Ventures in January 2016 as an Executive-in-Residence and Chief Executive Officer of 4:59 Therapeutics, a company seeded for identifying and acquiring innovative assets. Dr. Tartaglia has over 25 years of scientific and therapeutic product project leadership in the biotech industry. Prior to joining 5AM, Dr. Tartaglia served as a Partner at Third Rock Ventures where he played an integral role in the overall scientific diligence, formation and development of its portfolio companies. He has also served as Chief Executive Officer of Solstice Biologics and General Manager at GeneLogic. Before that, he was Vice President of Metabolic Diseases at Millennium Pharmaceuticals where he was responsible for the discovery and development of multiple therapeutic programs. Earlier in his career, Dr. Tartaglia did his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel. He completed his Ph.D. in biochemistry at the University of California, Berkeley in the laboratory of Dr. Bruce Ames and his B.S. in chemistry at the State University of New York at Albany. Dr. Tartaglia is based in the Boston, MA office.
Mark Saad
Board Member at Axsome Therapeutics, Inc. + more
Axsome Therapeutics announced Mark Saad as one of its Board of Directors in Sep, 2014. Mr. Saad is Chief Financial Officer (CFO) of RuiYi, Inc., a global therapeutic innovator which is advancing a pipeline of first in class monoclonal antibodies to validated G protein-coupled receptors (GPCRs). He previously served as CFO of Cytori Therapeutics, where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the COO of the Global Healthcare Group. Prior to UBS, Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney. Mr. Saad holds a B.A. from Villanova University.
Martin Babler
CEO at Principia Biopharma + more
Prior to joining Principia, Mr. Babler was President and Chief Executive Officer of Talima Therapeutics, Inc. Previously, he held positions of increasing responsibility at Genentech, Inc., most recently as Vice President, Immunology Sales and Marketing. He began his pharmaceutical industry career at Eli Lilly and Company focused on sales, sales management, global marketing and business development. Mr. Babler is a Guest Lecturer for the BioExec Institute at the Haas School of Business at the University of California, Berkeley. He also serves on the board of ZS Pharma and the BIO Emerging Companies Section Governing Board. He holds a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich. Mr. Babler also graduated from the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
Ruth Wexler
Executive Director at Bristol-Myers Squibb + more
Dr. Ruth Wexler joined the Bristol-Myers Squibb Company as Executive Director, Discovery Chemistry, (post-acquisition of DuPont Pharmaceuticals Company) and in the fall of 2002, she moved to Hopewell site in New Jersey where she currently heads the medicinal chemistry efforts directed at Cardiovascular Diseases. She was honored in 2004 as one of twelve Outstanding New Jersey Women in Research by the New Jersey Association for Biomedical Research. In 2011, she was a recipient of the Bristol-Myers Squibb Ondetti and Cushman award for her leadership role in the discovery of Eliquis®. She has been selected as the recipient of the 2015 E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. Ruth has co-authored over 190 peer-reviewed scientific publications and patents, and has contributed several review articles and book chapters largely in the area of cardiovascular research.
Matthew Cooper
CSO at Progenity + more
Matthew Cooper, Ph.D., DABT, MBA, is the Chief Scientific Officer of Progenity, Inc., a provider of complex molecular and specialized diagnostic medical testing. Matthew was formerly CEO and Founder of Carmenta Bioscience, a leader in preeclampsia diagnostic development, until it was acquired by Progenity in early 2015. Matthew also serves on the board of directors for the Preeclampsia Foundation, holds an advisory role for the SPARK translational research program at the Stanford School of Medicine, and leads the medical neighborhood at StartX, the Stanford start-up accelerator. Matthew has over 15 years experience in biomarker and drug development across the value chain. Past areas of specialty have included biomarker discovery and development, informatics, safety (toxicology and DMPK), and organizational/corporate strategy.
Mickey Kim
Director, Partnering & Strategy, Global Partnerships MedImmune + more
Director, Partnering & Strategy, Global Partnerships MedImmune Dr. Kim comes with over fifteen years of experience leading and executing a variety of collaborations and deals in the US and Asia. Prior to joining MedImmune, he was a healthcare venture capital investor with Canaan Partners and BioVentures Investors, an entrepreneur, and a strategy consultant with McKinsey and CSC Healthcare.
Michael M. Miller
Associate Director at Bristol-Myers Squibb + more
Creative, results-oriented, passionate, and strategic R&D leader with expertise that spans the gamut from Process Development to Medicinal Chemistry and from Alliance Management to Business Development. Scientifically-driven business professional with strong interpersonal, communication, consulting, and project management skills. A proven leader of multi-disciplinary teams across functional areas who has contributed to the nomination of five (5) clinical candidates throughout his tenure within six (6) Therapeutic Areas within Discovery and the advancement of two (2) candidates within Process Development. Current Lead within Research Collaborations for Fibrosis, Immunoscience, Virology, and Discovery Platforms who not only manages established relationships, but also works closely with R&D senior management, corporate BD, Finance, and Legal to seek out new business opportunities and alliances. A leader of the organization’s strategic in-licensing and out-licensing activities.
Sharon Cload
VP, Molecular Discovery Technologies, Bristol-Myers Squibb + more
Dr. Sharon Cload, served as Vice President of Research at Adnexus Therapeutics, Inc. and served as Vice President of Discovery of Adnexus Therapeutics Inc. since July 2008. Dr. Cload has more than a decade of experience in lead discovery and managing biotech-pharma partnerships. Prior to joining Adnexus, she spent seven years in lead discovery and technology development at Archemix Corp., most recently as Vice President, Aptamer Discovery. From 1996 to 2000, Dr. Cload developed small molecule discovery technologies for both RNA and protein targets at Anadys Pharmaceuticals (formerly Scriptgen Pharmaceuticals), a biotechnology company. Dr. Cload holds a Ph.D. in Bio-Organic chemistry from Yale University, and was an NIH post-doctoral fellow with Peter Schultz at the University of California, Berkeley. Dr. Cload received her BA in Chemistry at New College of the University of South Florida.
Patrick Gallagher
Licensing & Acquisitions at AbbVie Boston + more
Licensing & Acquisitions at AbbVie Boston, Massachusetts Biotechnology
Percy Carter
Head of Discovery Chemistry, Bristol-Myers Squibb + more
Head of Discovery Chemistry, Bristol-Myers Squibb
Richard Hughen
Consultant / Advisor to Life Science Industry + more
Consulting for life science companies on strategy, fundraising, market analysis and assessment, product development, regulatory and reimbursement. As products commercialize, I assist with product and market strategy, product management, marketing, PR, advertising and sales. Currently advising in the fields of molecular diagnostics (Scanogen), cardiology (Melys), information technology (Vigilant Medical), surgical devices (ScalPal) and wound care (Beeken). Reviewer for TEDCO’s Maryland Innovation Initiative and Life Science Investment Fund. Advisor to The Johns Hopkins University Biomedical Engineering School, Penn State University Springboard business plan competition, Oxbridge Biotech Roundtable (Onestart) and TEDCO-MERL.
Widya Mulyasasmita
Senior Associate, New Ventures at Johnson & Johnson Innovation + more
Widya joined Johnson & Johnson Innovation, California as part of the New Ventures team, supporting deals and collaborations across consumer, medical device and pharmaceutical sectors. Widya comes to Johnson & Johnson from McKinsey & Company, where she was a management consultant advising clients in healthcare and other industries on corporate strategy, lean operations, and organizational health topics. Prior to McKinsey, Widya worked at GE Ventures Healthcare as an Associate Intern, and she also co-founded a medical device startup called LapIQ, where she served as Chief Scientist developing biodegradable wound closure devices.
Steven Muneavar
Founder/Principal Consultant at Munevar & Associates + more
Munevar & Associates, Inc. is a life science technology development and commercialization strategy consulting company founded and led by Dr. Steven Munevar. The company is focused on identifying and connecting with cutting edge biomedical research/innovations that are poised for transformational impact on the healthcare space. Areas of Expertise/Interest: *Innovative technologies/applications as well as deep dive domain research and analysis *Biomedical science research and translation, data analysis, and communications *New venture creation, business strategy development, lean start-up methodologies, market research and analysis, corporate communications/marketing, resource navigations and development *Data analytics, statistical modeling, hypothesis testing, data visualization, data communications
Simon Greenwood
Chief Business Officer at Allakos Inc + more
Simon has over 20 years of experience in the heathcare industry. Prior to joining Allakos, Dr Greenwood was Investment Director for the Roche Venture Fund, where he led investments in 23andMe, Allakos, Biodesy, CytomX (NASDQ: CYMX), DVS (acquired by Fluidigm), Epic Sciences, Horizon Discovery (AIM: HZD), Maculogix, ProActa and Stratos. Prior to his role at the Roche Venture Fund, Dr. Greenwood was the head of GenenFund, Genentech's corporate venture fund, and he also held roles in research and business development at Genentech. Dr. Greenwood holds a Ph.D. in Genetics and Development from Columbia University College of Physicians and Surgeons, where he was a Fulbright Scholar.
Europe Mentors
Deborah Harland
Partner, SR One + more
I joined SR One in 2005 to establish the firm's European investment office. I have extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during more than 20 year tenure in the pharmaceutical industry. I am currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star and VH Squared.
Matthew Foy
Partner, SR One + more
I joined SR One in 2011 to take the lead in investing SR One's UK biotech fund. Prior to joining SR One I worked as a consultant for Longbow Capital Partners in London, and before that I was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm.
Sarah Holland
Head of Europe, External Science & Partnering at Sanofi + more
Responsible for cultivating relationships and bringing forward innovative external opportunities from key stakeholders located across Europe. Groups based in France, Germany, the UK, Israel and Russia form the European External Science and Partnering team, charged with building a deep network of external collaborators and working to become the partner of choice for all external innovation sourced across Europe. Specialties: Cross-functional team leadership, pharmaceutical M&A, business development, strategic planning and global marketing.
Matthias Essenpreis
Chief Technology Officer, Roche Diagnostics + more
I am the Chief Technology Officer, Diagnostics at F. Hoffmann-La Roche Ltd. Prior to that, I was the Head Global Research and Technology of Roche Diabetes Care.
Claire Brown
Investment Manager, Alderley Park Ventures + more
I manage a life science focused seed fund leading the identification, evaluation & diligence on opportunities for investment (devices, products and platform technologies) having previously, at AstraZeneca, led all aspects of in-licensing business development activities from ‘search and evaluate’ to delivery of business case proposals.
Nooman Haque
Director of Life Sciences, Silicon Valley Bank + more
I lead the European life science & healthcare business at Silicon Valley Bank, supporting early and late stage companies with their financing needs. We work across all sub-sectors including biotech, medtech, and digital health.
David Phillips
Partner, SR One + more
I joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. I bring a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. I have significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.
Declan Jones
VP Neuroscience Scientific Innovation, Johnson & Johnson Innovation London + more
I am Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation London. I previously worked for GSK’s Centre of Excellence for External Drug Discovery (CEEDD) where I was responsible for creating scientific strategies and managing processes from preclinical to Phase II state programs across all therapeutic areas.
Elena Fernandez-Kleinlein
Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation, London + more
I am Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, London. Previously as Senior Director of R&D Global Topical Health Care for Johnson & Johnson Consumer & Personal Products, I was responsible for seeking innovative products and claims pipelines within the franchise and oversaw the product development program for iconic brands such as Band-Aid Adhesive Bandages, Johnson & Johnson’s Red Cross and other regional brands like Compeed, Neosporin and Bengay.
Karin Conde-Knape
Vice President of Cardiovascular & Metabolic Scientific Innovation, Johnson & Johnson Innovation, London + more
I am VP Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London. Previously, I was Global Head of Discovery in the CVM DTA at Roche where I was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, I was responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide.
Kurt Hertogs
Platform Innovation & Incubator Strategy Leader, Johnson & Johnson Innovation, London. + more
I am Platform Innovation & Incubator Strategy Leader at Johnson & Johnson Innovation, London. Previously, I held research and early stage development roles at Tibotec and was involved in the discovery and pharmacological profiling of major anti-infective drugs like Prezista, Intellence, Edurant, Incivo and Simeprevir.
Michal Silverberg
Senior Director, External Innovation, Takeda Ventures + more
Currently based in Israel, I joined TVI in September 2014 as Senior Director for External Innovation with a primary focus on Israel and Europe. Since 1998, I have held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies.
Chris Brown
Director, Worldwide Business Development, GSK + more
I joined GSK as Director, Worldwide Business Development in 2011. Prior to that I was Director, Worldwide Business Development at Pfizer.
Rick Cousins
Senior Director, Alternative Discovery & Development, GSK + more
I am leading the creation of a new pre-Discovery Performance Unit (DPU) at GSK hearing disorders within the Alternative Discovery & Development organisation at Stevenage. I have been involved in programmes at all stages of drug discovery on a wide variety of targets for many therapeutic areas including anti-virals, anti-fungals, cardiovascular, respiratory, inflammation, neurology and metabolism.
A. Maria Dahl
Executive Business Development Director, AstraZeneca + more
My responsibilities are for negotiating oncology licensing and collaboration agreements. I have more than 12 years experience in business development and portfolio management from the US and UK pharmaceutical and biotech industry. I have also been a non-executive director on the board of a private UK biotech company, and also previously co-chaired or been a jury member in US and French business plan competitions.
Simon Hollingsworth
Executive Director, Oncology Innovative Medicines & Early Development, AstraZeneca + more
I'm responsible for development and delivery of AstraZeneca’s portfolio of Stratified Medicine Studies, partnered Stratified Medicine initiatives (National, European, US, Asia) and basket studies, and Senior Project Director in Oncology Early Clinical Development. I have >20 years experience in drug and therapeutics development across industry (AstraZeneca, Roche/Genentech) and academic (University College London, King’s College London) careers focused in clinical and translational science, and personalised healthcare in oncology, inflammation and cardio-/vascular fields.
Lynne Murray
Associate Director, Partnering & Strategy, MedImmune + more
After joining MedImmune, I initially focused on the fibrosis research efforts, both internally and with external collaborators and have since gained an MBA. I'm now Partnering & Strategy group at MedImmune and my research interests span the underlying pathways promoting the effects of injury, inflammation and I have successfully transitioned 3 therapeutics into Ph2.
Barbara Domayne-Hayman
Chief Business Officer, Autifony Therapeutics + more
I am a company builder and deal-maker in biotech, who has successfully transitioned from working in large organisations to an entrepreneurial environment and mindset. I want to make a real contribution to society through the commercialisation of new science. I also have a passion for opera and playing the harp and piano.
Davidson Ateh
CEO, BioMoti + more
I am a co-inventor of the Oncojan™ platform and CEO of BioMoti, leading on operations, product and business development activities with my interdisciplinary scientific background in the physical and life sciences. I have a successful track record of financing disruptive ideas, progressing projects and gaining awards.
John Beadle
CEO, PsiOxus Therapeutics + more
I am an entrepreneur with a strong medical and business background. In 2010, my leadership of Myotec Therapeutics and Hybrid Biosystems led to their combination to form PsiOxus Therapeutics Ltd.
Will West
President & CEO, Cancer Targeting Systems (CTS) Inc. + more
I am a biotechnology chief executive, with experience spanning basic research through to late stage clinical trials (biotech, pharma/corporate, public funding body).
Michelle Scott
Biologics Solution Director, Covance + more
I am an experienced senior business leader and biological medicines development expert with a unique combination of strategic, business development, regulatory affairs, scientific and management expertise gained in the biopharmaceutical sector.
Inga Deakin
Healthcare Ventures Associate, Imperial Innovations + more
I specialise in investments across medical devices, therapeutics, diagnostics, and healthcare, including digital health.
Jonathan Tobin
Associate, Healthcare Ventures at Imperial Innovations + more
I am a life science specialist with experience of early and later stage venture capital deals, specialised in therapeutics and diagnostics. Board director of two specialist diagnostics companies, board observer of two therapeutics companies.
Kathryn Owen
Healthcare Ventures Associate, Imperial Innovations + more
I focus on investments into early stage therapeutics and diagnostic opportunities from first-class research institutions within the Oxford-London-Cambridge triangle.
Mark Phillips
Executive advisor to biotech and healthtech companies + more
I am a senior executive with over 30 years experience in the pharmaceutical, diagnostics and life sciences industries. I have led global teams in research and development, and in manufacturing to create new businesses and transform performance. I am passionate about building new capabilities in teams and individuals (through coaching), and working with smaller businesses and academia to translate ideas and strategy into products and results.
Nicholas Edwards
Chairman of MedInnovate, Kinapse & Oxtex + more
I am a medically qualified doctor with 25 years experience of consulting, with a particular focus on healthcare, life sciences and pharmaceuticals. I work with large pharmaceutical companies, regulatory bodies, start up and small businesses in the healthcare, pharmaceutical, biotechnology medical or diagnostic devices area. I am interested in supporting the rapid translation of medical innovations into commercially successful businesses, including technology transfer from universities to spin outs.
Andy Sandham
Partner, Syncona Partners + more
I am a Partner of Syncona Partners LLP. Previously I was a co-founder, Chairman and CEO of Kymab. I have played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals.
Hakan Goker
Investment Director, MS Ventures + more
I am a private biotechnology and medtech investor instrumental in the formation, management and business strategy of new companies, currently a director at MS Ventures, and previously a partner at Aescap Venture, with experience from Atlas Venture and postdoctoral molecular biology training.
Sara Núñez-Garcia
Senior Associate, Sofinnova Partners + more
Sara Núñez García joined the Life Sciences team as an Associate in 2013; Sara focuses on investments in the biopharmaceutical sector. Prior to Sofinnova Partners, Sara worked in the Licensing and M&A team at Onyx Pharmaceuticals in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space. Previously, Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages of novel chemical entities. In addition, Sara led transfer-of-knowledge projects with several universities in Amsterdam. Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed inhibitors for oncology targets. She has a PhD in Chemistry from the University of Manchester; her doctoral research used a combination of experimental and computational techniques to design and synthesize transition state inhibitors. Sara has published eighteen peer-reviewed articles and patents. Sara also holds an MBA from INSEAD (finance major).
Rachel Moss
Associate Principal, Pharmaceutical and Medical Products Practice, McKinsey & Company + more
I joined McKinsey after completing a postdoctoral fellowship at Columbia University Medical Center following my PhD in Neuroscience at King's College London.
Shane Gannon
Consultant, McKinsey & Company + more
I am an Associate in the UK/Ireland office. Since joining McKinsey in 2012, I have mainly worked in the pharmaceutical and healthcare sectors covering topics such as M&A, quality assurance, sourcing, operations and transformational change.
Hakim Yadi
CEO, Northern Health Science Alliance + more
I am the CEO of the Northern Health Science Alliance (NHSA), a new company limited by guarantee established to develop and integrate the biomedical research capabilities of the founding Universities, NHS trusts and Academic Health Science Networks.
Brewster Barclay
Business Development Director, Zuhlke Engineering + more
I have 20+ years high-tech industry experience in software and manufacturing. I'm passionate about technology and introducing new products and services to markets that have never existed before.
Julius Bruch
Associate, McKinsey & Company + more
I joined McKinsey in 2014, after working on clinical trials for neurodegenerative diseases and undertaking research on PSP pathogenesis at the German Centre for Neurodegenerative Disease Research.
Caroline Austin
Transaction Director + more
Caroline is a Transaction Director within the Business Development Operations function at AstraZeneca and is based in Cambridge. She has been working in Business Development for 15 years and has worked on the search and evaluation of opportunities, negotiation of a variety of deal types including academic partnerships, licensing of discovery and development stage assets as well as on market products, divestment and acquisition, and has also led alliance management and business integration activities. Caroline has broad experience of working in transactions in many different therapeutic areas including Respiratory, Inflammatory, Cardiovascular, Diabetes and Infectious diseases. Prior to working in Business Development, Caroline worked in R&D in the Respiratory and Inflammation Therapy area at AstraZeneca. Caroline’s academic qualifications and experience include: PhD in Pharmacology, University College London and post-doctoral research at the Institute of Otorhinolaryngology, University of London and in the Division of Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine.
Lucas de Breed
Investment Director + more
- PhD in Mol Bio/BioChem UCL/Cancer Research UK - 3 years of biopharma strategy consulting in EU/US - 2 years of investing/start-up activity in the US during Stanford MBA - board observer in 2 portfolio companies of Inkef Capital
John Easton
Head of Business Operations + more
John holds a BSc and a PhD in Physiology, both from the University of London. After a post-doctorate position at the London Hospital Medical School, John joined the CNS team at May & Baker (then a division of Rhone Poulenc) in 1985. In 1988 he co-founded a start-up CRO (Campbell Charles Associates), moving on in 1992 to be Clinical Research Director at Bios and then again in 1996 to join IBAH (later Omnicare Clinical Research, now Theorem) where he held a number of positions including Vice President, International Business Development and Regional General Manager for Northern Europe. John joined PAREXEL in 2001 to head a customer business unit and moved to HQ in Boston early in 2002 to run the global sales organisation for the Clinical Research Services division. He joined AstraZeneca in 2004 to head Global Clinical Outsourcing and then joined the newly formed Strategic Partnering & Business Development team at AstraZeneca in January 2007. He has held a number of roles as the Business Development team has evolved and is currently the Head of Business Operations for BD, a role which encompasses most of the back-office functions for BD in addition to leading the Due Diligence team.
Jenny Horsfield
Transaction Director + more
Jenny is a Transaction Director within the Business Development Operations function at AstraZeneca. She has been working in Business Development for 7 years and has worked on search and evaluation of opportunities and the negotiation of a variety of deal types including early stage collaborations, on market products, divestment and acquisitions across many different therapy areas. Jenny also has significant experience of working on commercial partnering deals and has Asia expertise having lived and worked in Japan and China. Jenny has a commercial and finance background and is a qualified management accountant.
Hitesh Sanganee
Director of Emerging Innovations + more
Hitesh is currently a Director in the Emerging Innovations group. His main role is to participate and execute the open innovation strategy within the innovative medicines function in AZ. This involves collaborating with academic institutions such as MRC (UK) NIH (US) to identify novel uses for our medicines and hence build a portfolio of projects. He has also been involved in internal ideation events (open innovation within a large company setting) in AZ. Previously his role was in the science function within the AstraZeneca. His main role was as a chemistry cluster lead inputting into external and internal drug repositioning projects and potential in-licensing projects. Other roles also have included CDL (candidate drug leader) working on regenerative medicine, and a Team Leader in the respiratory & inflammation therapeutic area. He originally received his degree and DPhil from Oxford University in chemistry and subsequently held a postdoctoral research position at Florida State University. He joined AstraZeneca as a Medicinal Chemist in 1999 conducting research within respiratory & inflammation related disease areas and has led teams to successful milestone transitions in all phases of drug discovery. He has >40 patents and publications.
Anna King
NHS - Commercial Director, Health Innovation Network, AHSN + more
After a career in healthcare investment banking and investment, I now focus on the spread an adoption of value enhancing innovation in the NHS.
Lorraine Webber
UK Head of the Emerging Innovations Unit, AstraZeneca R&D + more
This is a small, externally-focused R&D group primarily involved in drug re-purposing through pioneering ‘open innovation’ partnerships with a global network of external investigators, as well as internal drug repositioning. Lorraine has a broad background in drug development and, prior to joining the Emerging Innovations team, led drug projects in early clinical development in a number of therapy areas including respiratory, dermatology and women’s health. Lorraine has also held roles in the global commercial organisations at AstraZeneca and Novartis. Lorraine holds a degree in Medicine from Guy’s and St. Thomas’s Hospitals, London.
Victor Dillard
COO & Founder of Desktop Genetics + more
Since founding Desktop Genetics ( in 2012, after winning Life Science Start-Up of the Year at the CUE competition, I have led the company’s business development and CRISPR genome-editing initiatives, placing the fast-growing company at the forefront of CRISPR therapeutics research. As the one responsible for the company's financing, I have a track record of raising c $3M in business financing and closing c$1M in customer deals. I hold an MEng in Chemical Engineering from Imperial College London and an MPhil in Bioscience Enterprise from the University of Cambridge. I regularly speak at genome editing conferences and workshops on the CRISPR technology, it's application in drug discovery and development, large scale functional genomics screens and personalised medicine. I support the promotion of entrepreneurship in schools and universities by regularly speaking and mentoring at university clubs and business plan competitions.
Iwan Roberts
COO Puridify + more
Co-founder of Puridify (OneStart 2013 winners) - Licensing tech from University - Business Plans, market analysis etc... - Fundraising Private & Public - Collaboration/MTA agreements - IP - HR Academic background - Stem Cells, Cell Therapy, Bio-pharmaceutical manufacturing
Robert Sugar
Life Sciences Software Architect at Intel + more
I am a computer scientist by training, working as a software architect for Intel, looking primarily at optimising bioinformatic pipelines. I have recently finished my PhD at the European Bioinformatics Institute in Cambridge, UK analysing chromosome conformation data using next generation sequencing. Previously I have worked for Microsoft Research and Nokia Networks on a wide range of topics, including sensor networks, robotics, data compression or pedestrian navigation.
Thomas Saylor
Non-executive Director, Arecor Limited + more
I have served as CEO of several emerging biotech companies both in Europe and Asia. Most recently I was as CEO of Arecor Limited, a British company focused upon enabling the next generation of therapeutic proteins and vaccines through advanced formulation technologies. Previously, I was CEO of Sirus Limited, a drug targeting and delivery company based in Cambridge, England. Prior to joining Sirus, I was Chairman and founder of Lotus Healthcare Corporation, an Asian-based fully integrated pharmaceutical company. I am also actively involved in development of public policies as Chairman of the SME Platform and Vice-Chairman and a member of the board of EuropaBio, and serve on the scientific advisory boards of several universities.
Jane Dancer
Chief Business Officer at F-star + more
Jane Dancer is Chief Business Officer at F-star, a biopharmaceutical company based in Cambridge, UK, which is developing bispecific antibody immuno-oncology products. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.
Megan Morys
Deputy Director of CASMI + more
I am the Deputy Director of a medical research institute and mentor to a number of high-tech businesses, as well as previously working in a number of different industries in the private sector. I have experience of idea creation and selection, market assessment, investment readiness and fundraising, people management and team structures. I have a particular interest in high-tech innovation.
Sam Gray
Partner, Apposite Capital + more
Healthcare investor and deal maker with extensive experience of growing healthcare companies through private equity growth and buy out investments and venture capital.
Saurin Badiyani
Healthcare Solutions Lead at The Janssen Pharmaceutical Companies of Johnson & Johnson + more
Healthcare innovation professional with interdisciplinary applied research, product prototype & service development, consulting and business development experience gained throughout Europe. Managed multiple concurrent projects from ideation to completion spanning across multiple industry verticals including IT, healthcare, pharma, biotech and manufacturing. Managed multiple concurrent projects from ideation to completion; including financial, operational and strategic planning and management.
Tristram Norman
Co-founder and CTO of Simprints + more
I'm the Co-founder and CTO of Simprints, a Cambridge based start up that recently won Business Weekly's "Start up of the year" and Tech Crunches Europas award "Changing lives for good". My background is in software development with a focus on large platform architecture and big data. Simprints has raised over 1 million in equity free funding to date.
Kate Rowley
Director, Healthcare + more
Kate is an Investor Director with IP Group, she is responsible for identifying and commercialising intellectual property in the life sciences area with specialisation in business building, sales and marketing. Kate has over 20 years’ experience in the life sciences sector, working in the NHS, large pharma, public and private sectors.
Dirk Dembski
Managing Director, Naton Medical Group + more
I have been the managing director of the Naton Medical Group for over a year and a half. Before this I worked for Olympus Biotech International as the (VP of Sales, Marketing and Business Development) and Small Bone Innovations (International Sales and Marketing Director).
Aric Orbach
Head of Pharmacology at Teva Pharmaceuticals + more
I Graduated from the Koret School of Veterinary Medicine (Hebrew University) in 1995. Following my graduation I operated a veterinarian clinic and worked as a study director at Vetgenerics Research G. Ziv Ltd. I joined Teva in 2001 . Since then I have conducted various roles in the R&D, starting out in the non-clinical safety department then moving on to project leadership where I was responsible for development of projects at early stages. I am currently heading the pharmacological department. The unit is responsible for pharmacological investigation in pre-clinical models conducted as part of development process of novel drug candidates.
Susan Hill
Founder and CEO at Clipper Biotech + more
I am currently working in business development/strategy with rare disease companies. Prior to this I led Alexion Pharma’s business development activities in Europe, having previously spent 8 years as a Director of business development and portfolio development with Serono / Merck KGaA. I have experience evaluating many different drug development proposals across lots of therapy areas, and working with teams to refine development plans, identify risks, define the commercial opportunity and summarize the key value proposition.
Catherine Merry
Senior Associate at Olswang LLP + more
Catherine advises on the design, implementation and operation of employee share incentive arrangements including tax efficient share plans and bespoke share and cash incentive arrangements for a wide range of companies. She has vast experience advising start-up companies on how best to incentivise their founders and employees and also assists international clients wishing to extend their employee share incentive arrangements to the UK and Europe. Catherine was a medical physicist and worked in a number of London hospitals prior to qualifying as a solicitor.
Niall McAlister
Partner - Olswang LLP + more
Niall has over twenty-five years' experience as a corporate lawyer and has a wide experience of mergers and acquisitions, joint ventures and private equity and venture capital transactions, acting for start-ups, SMEs, large corporates and institutional investors. He has particular experience representing life sciences clients, having advised both commercial entities and medical research charities on a range of transactions in the sector. He is recognised in directories for his expertise as a corporate and venture capital lawyer in the life sciences sector.
Robert Stephen
Co-Chair Life Sciences Group - Olswang LLP + more
Dr Robert Stephen, Partner and co-chair of Patent Prosecution, co-chair Life Sciences. Robert's focus is on helping his clients develop and exploit their IP to maximise company value. He has worked with a number of successful start-ups, including Kymab in Cambridge UK and Insmed in the US. Robert has experience in drafting, filing and prosecuting patent applications before the UK and EPO, patent licensing, global patent strategy, patent term extensions and portfolio management. He has been involved in over 50 EPO oppositions and appeals. Robert has a particular interest and expertise in inventions made in the fields of medical devices, pharmaceuticals, biochemistry, biotechnology, cell biology, genetics and immunology, including protein and peptide based medicines, vaccines, antibodies, nucleic acid based medicines, diagnostic methods and diagnostic apparatus.
James Taylor
Director Business Development GlaxoSmithKline + more
Over the last 5 years I have been based in Brussels with GSK as Director of Corporate Development where I worked on a series of transformative deals. I led the sale of the meningococcal vaccines business to Pfizer in a complex business carve-out transaction. I have also led a wide range of clinical stage and platform technology in biological drug development. Prior to joining GSK I was Chief Business Officer at UK BioPharma companies Summit plc and Cellzome Inc and have broad experience leading partnering deals and fundraising in the BioPharma industry. My early career was with AstraZeneca in the UK, US and China.
Astrid Hannich-Walter
Director Business Model & Health Care Innovation, Boehringer Ingelheim GmbH + more
Director Business Model & Health Care Innovation, Boehringer Ingelheim GmbH
Yiu-Lian Fong
Global Diagnostic Innovation, Johnson & Johnson Innovation + more
20 years of broad and progressive management and leadership roles in IVD, pharmaceutical and biotechnology industry. Extensive experiences in R&D leadership roles for portfolio / program / project / people management, strategic planning and execution for IVD, Blood Screening, protein therapeutics and vaccines, and for technology development. Proven track record of establishing R&D functional excellences, developing innovative technologies and directing/leading technical due diligence for M&A and licensing; managing R&D budgets, directing and managing multidisciplinary teams and functional departments, advancing R&D pipelines, and meeting/exceeding organization and program objectives. Track record of building talent pipelines and extensive experience in talent management. Experiences and roles/responsibilities include: • Develop and/or execute business strategies for genetics, oncology, infectious disease, metabolic disease, and neuroscience •Develop and drive technical strategies for drug and companion diagnostics co-development • Recruit and develop talents, build functional departments and project teams, develop and implement product development and project management tools and processes, grow organization. • Direct, manage and oversee R&D functions for biological drug and vaccine development, blood screening, and IVD product development: Biomarker Development, Assay Development, System and SW Engineering, System Integration, Design Transfer, Technology Transfer, Technology Development, Process Development and Validation, Pilot Production, Analytical Method Development and Method Validation, QC Testing, Project Management (PMO) and Scientific Affairs. •Drug development CMC lead or core team member: Phase I, II and III IND, and NDA/BLA submissions for biological and blood screening. •Technology assessments and strategic alignment for M&A and BDL initiatives •Strategic alliance with partners and vendors, drive and manage collaborations
Tom Youldon
Associate at McKinsey & Company + more
Tom Youldon Associate at McKinsey and Company Currently Associate at McKinsey & Company Previous leadership positions: Enforcement Director, Monitor Head of Strategy, Office for Budget Responsibility Senior Policy Advisor, HM Treasury
Paolo Vicini
Senior Director at MedImmune + more
Head of the Medlmmune Cambridge department of Clinical Pharmacology and DMPK (CPD), one of three global Medlmmune sites providing PKPD, pharmacometrics and bioanalytical support for the biotherapeutic products pipeline. Responsible for establishing strategy, direction, and objectives for the CPD site, and ensuring progress towards objectives. Accountable for all aspects of CPD for products at discovery, nonclinical and clinical stages of development Collaborate with bioanalytical and translational CPD scientists on the development, validation, and conduct of PK, immunogenicity, and biomarker assays. Active contributor to R&D and corporate governance committees and the strategic direction of the broader research organization, including harmonization between sites.
Carina Namih
Co-Founder and CEO at HelixNano + more
Carina Namih is an entrepreneur and regular speaker on technology in culture and society. She is the CEO and co-founder of HelixNano, a health technology company backed by Johnson & Johnson Innovation. The company lies at the rapidly emerging intersection of genomics, software and medicine. Carina is recognized as the BioBeat Rising Star of British Biotech and as a World Economic Forum Global Shaper. She shares her experience of building disruptive, technology-led businesses in Silicon Valley as an advisor to corporates and governments. Carina is an alumna of both Oxford University and Singularity University: Google’s futurism think-tank based in California.
Louise Fairburn
Vice President. Global Commercial Learning Academy at AstraZeneca + more
A global pharmaceutical business leader experienced in marketing, sales, commercial operations and corporate affairs. Demonstrated ability and track record of building, leading and motivating large cross-functional teams across geographical boundaries and cultures. Demonstrated ability to lead innovation and change in large organisations and teams. More than 22 years experience in the pharmaceutical industry with more than 10 years in senior roles
Reese Dandawate
Associate at McKinsey & Company + more
Experienced in advising the Board of Directors and Executive Committee on business responses to macroeconomic and industry developments at Macquarie Group.
Laurent Morlet
Digital Innovation at Johnson & Johnson Innovation + more
Laurent is Digital Innovation Lead at Johnson & Johnson Innovation, London. Previously, Laurent helped the Janssen Drug Evaluation group manage scientific information and information systems. Laurent was also a Business Relationship Manager working with different business units over time. Laurent holds a PhD in Pharmaceutical Sciences from the University of Nantes, France. He has also gained additional diplomas in photobiology and drug delivery systems.
Sarah Haywood
CEO, MedCity + more
I am an experienced leader, with a background in policy and in management. I am currently using my strategic thinking skills to develop London as a recognised centre of excellence for Life Sciences research and development. As a civil servant in the UK department for Business Innovation and Skills, I have specialised in UK and European employment law, rights and the labour market - I led the development of the Government's flexible working and shared parental leave policies. I have a strong interest in people management - development, coaching and supporting people to achieve their best. Over the last year I led a project within the department to refocus on the importance of people management and why it really matters. I am an experienced assessor, mentor and coach. I have a background in HR, from my time in Novartis. I am active in supporting the case for flexible working and have considerable experience in managing and developing teams where members employ a whole range of flexible working patterns.
David Meinhart
Director, Mendi Associates + more
Director at Mendi Associates.
Charles MacKinnon
Director, Integro Care Solutions + more
Integro Care Solutions provides citizen centred assessment and delivery of personalised support to improve the health outcomes of populations. We do this by developing cloud-based software solutions for assessing, co-ordinating, managing and monitoring the provision of patient care and assisted living support around the needs of the individual.
Chris Jones
Chairman at Mologic Ltd + more
Currently Chairman of Mologic Ltd, NED for Deltex Medical, and Special Advisor to MediSeive and StableLab, Chris is a US national who came to the UK in 2008 to become CEO of GlySure. From 2008-2015 he led the development of the world's first continuous intravascular glucose sensor from laboratory proof of concept to CE approval. Prior to joining GlySure he was CEO of Tensys Medical developing and commercialising the first clinically acceptable, continuous, non-invasive blood pressure monitor resulting in the sale of the company in 2008. Chris also spent nine years with Nellcor Inc, a division of Tyco Healthcare, most recently as VP of Marketing responsible for the $700M WW pulse oximetry and critical care businesses. Prior to this, he spent six years in sales and marketing management positions at BioGenex Laboratories.
Imran Mahmud
Consultant, McKinsey & Company + more
I help public and private sector clients across Pharma, MedTech and healthcare solve big, tough problems: - M&A and divestiture - Commercial transformation - strategy - drug launch - market access - corporate finance - marketing & sales
Justas Grigalauskas
Engagement Manager at McKinsey & Company + more
Engagement Manager at McKinsey & Company.
Samantha Macro
Head of Finance, Medimmune + more
Head of Finance - Medimmune Cambridge (formerly Cambridge Antibody Technology)
Oliver Sexton
Investment Director, Midven + more
Oliver Sexton joined Midven in April 2014 to manage the Rainbow Seed Fund’s synthetic biology investments. Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics. Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy. Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.
Alberto Di Gennaro
Associate at McKinsey & Company + more
Associate at McKinsey & Company
Irina Haivas
Board Observer, GNS Healthcare + more
Irina is a healthcare specialist with a background in medicine and management consulting. She previously spent seven years with Bain & Company, where she was a leader in the European healthcare practice, and brings a wealth of experience across Europe, US and emerging markets to the firm. Irina has advised multiple private equity funds on healthcare due diligence and post-acquisition projects, and has worked directly with pharmaceutical, biotechnology, and healthcare services companies on strategic initiatives including growth, business models, R&D and innovation, M&A, organisational development and operational improvement. Irina has a first-in-class degree in Medicine, and studied at Iasi Medical University in Romania, Freiburg University in Germany as Rotary Scholar and Harvard Medical School. She also holds a MSc with distinction in International Health Policy from London School of Economics. A native Romanian speaker, Irina is fluent in English and German and is conversational in French and Italian.
Maryam Atakhorrami
Group Leader/ Industrial Partnerships Manager, UCL + more
Dr Maryam Atakhorrami is an Industrial Partnership Manager with Translational Research Office in UCL. She works with key stakeholders of Faculty of Medical Sciences, to identify, create and manage strategic industrial partnerships for selected priorities of UCL in medical sciences.
Daniele Di Mattia
Junior Associate, McKinsey & Company + more
Junior Associate at McKinsey & Company.
Natasa Kovacevic
Engagement Manager, McKinsey & Company + more
Engagement Manager at McKinsey & Company
Anthony Gemmell
Senior Director, Transactions, Johnson & Johnson + more
Anthony is Senior Director of Transactions for Johnson & Johnson Innovation, London. Previously, Anthony worked within several business development roles in Johnson & Johnson Pharmaceutical Group Business Development including New Business Development, Mergers & Acquisitions and New Ventures, and has completed a wide variety of business development, licensing, acquisition and divestment assignments. Prior to joining the Johnson & Johnson Family of Companies, Anthony had management roles in the UK and EMEA in New Product Development and Business Unit Management with Lilly, Servier and Bristol Myers Squibb spanning multiple disease areas. He started his career teaching Biological Sciences in secondary education.
Nicki Thompson
Chief Business Officer, Phico Therapeutics + more
Nicki joins Phico from F. Hoffmann-La Roche Ltd, where she held the position of VP and Global Head of External Drug Discovery. In this role, Nicki built Roche's first external discovery team and pipeline, leveraging innovative partnership models with biotech and entrepreneurs including Roche's partnership with Spero Therapeutics, targeting drug resistant bacterial infections.
Lilian Alcaraz
Senior Director, Medicinal Chemistry Lead, Johnson & Johnson Innovation + more
Lilian is the Medicinal Chemistry Lead, for Johnson & Johnson Innovation, London Lilian has over 16 years’ experience in Medicinal Chemistry gained through working in both large pharma and CRO environments. Before joining Johnson & Johnson Innovation, Lilian was Senior Director of Chemistry at Charles River (Argenta). In this role, he co-headed of the chemistry department and was the Collaboration Leader of a large multidisciplinary tri-party partnership overseeing the delivery of multiple drug discovery projects. Prior to that, Lilian spent 13 years at AstraZeneca advancing in various leadership roles culminating as a Principal Scientist. During his time at AstraZeneca, Lilian gained extensive experience in lead optimization, lead identification and library design and synthesis. He was a member of the milestone review group for Respiratory and Inflammation research area and led improvement projects aimed at enhancing strategic component of Candidate Drug Discovery.
Georg Buchner
Licensing Director Europe & Israel, Amgen + more
A highly motivated business minded professional with excellent communication-and-interpersonal skills and international experience. My scientific background, sound commercial experience, and ability to network have accelerated my progression from science, through consulting to business development & licensing have enabled me to build strategic relationships across the life sciences industry and close a reasonable number of deals. I am an Italian and German native speaker and have a PhD and a post-doc from Kings College London and MBA from University of Cambridge. I am committed to pursue a career in business and corporate development in the life sciences industry. Specialties: technology-product licensing, scouting, termsheet- contracts negotiation, presentation skills, networking, strategic and financial analysis and modelling of licensing opportunities, e.g market research, competitor and benchmarking analysis, risk-adjusted NPV-based deal valuation, business-marketing plans, M&A, account management, business development, scientific and commercial analysis.
Mitchell Harris
Consultant, McKinsey and Company + more
Mitchell Harris joined the Civil Service on the Ministry of Defence Fast Stream where he covered wide range of issues including strategy, policy and parliamentary relations. In early 2013 he moved to the Cabinet Office as Assistant Head in the Cabinet Office's Programme Management Office for Civil Service Reform. In June 2013 he was appointed Deputy Private Secretary to Oliver Letwin, the Minister for Government Policy where he led on Foreign Affairs (Defence, Diplomacy, International Development), Public Services (Health, Education, Work and Pensions), Energy and Climate Change. Mitchell is now a management consultant at McKinsey and Company, an advisor to leading organizations across the private, public and social sectors.
Claudia Pradel
Engagement Manager at McKinsey & Company + more
Engagement Manager at McKinsey & Company
Davidson Ateh
CEO, BioMoti + more
Davidson Ateh is a health entrepreneur. He has an interdisciplinary scientific background in the physical and life sciences having completed a BEng in Biomedical Materials and a PhD in Bioengineering at Queen Mary University of London. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School (University of Strathclyde). Davidson has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti candidates have the potential to be groundbreaking cancer therapies for patients in need.
Purvi Gupta
Associate, McKinsey & Company + more
Associate at McKinsey & Company
Craig Rhodes
Business Innovation Manager, Intel Corporation + more
Business Innovation Manager in Health and Life Sciences Intel Corporation. Lead interdisciplinary healthcare innovation explorations that define new solutions to drive Intel’s business in the Health & Life Sciences (HLS) Sector. Defining all business functions of the solutions being incubated, including defining business strategy, business models, ecosystem and partnering strategies as well as Intel engagement.
Ned Wakeman
Director, The BioHub at Alderley Park, The BioCity Group + more
AstraZeneca has established a ‘BioHub’ at its Alderley Park site in Cheshire. Fully owned by AstraZeneca, the BioHub has been set up to allow pharmaceutical and life science companies to take advantage of the world class facilities available at the site, while operating entirely independently. The BioHub is being managed by BioCity, a leading bioscience incubator, on behalf of AstraZeneca.
Keith Powell
Chairman, Domainex + more
Keith Powell was appointed to Chairman of Domainex in 2007, having previously been the company's Chief Executive Officer. Keith is a serial entrepreneur and has extensive experience in the management of large and small biotech companies, most recently as CEO of PolyTherics. In 2007 PolyTherics secured £2.3M from a portfolio of investors and he successfully led SPEAR into an $8.5M series B financing round. Keith was formerly Senior Vice President of Maxygen, a protein modification company, where he was responsible for the execution of research partnerships that generated more than $20M of revenue before taking into account milestone and royalty payments. Prior to joining Maxygen, Keith was Head of Intellectual Property and Head of Discovery at Zeneca.
Nikhil Prakash
Associate at McKinsey & Company + more
Associate at McKinsey & Company
Emma Barton
Associate Director, Corporate Strategy & Development at AstraZeneca + more
Experienced Business Development professional with a track record of successful transactions of a variety of deal types, including complex and bespoke deal structures. Led the transactions for AZ's innovative Colorectal Cancer Collaboration which was awarded the Scripp prize for Best Partnership Alliance in 2011. Results orientated, conscientious, diligent and enthusiastic individual with extensive experience in leading transactions including: scouting, scientific and commerical evaluation, business case preparation, stake holder engagement, term-sheet and contract drafting and negotiation across pre-clinical and early stage clinical development of oncology products. Significant experience of negotiation of license and collaboration deals with pharmaceutical comanies, biotechnology companies, academic and charitable organisations within UK, Europe, US and Asia. Excellent communicator, enjoys working with and leading international multi disciplinary teams across a range of geographies. Line management experience, supported numerous individuals developing their professional skills via coaching and mentoring.
Kimchi Hoang
Associate, McKinsey & Company + more
Associate at McKinsey & Company
Grace Chiang
Business Analyst, McKinsey & Company + more
Business Analyst at McKinsey & Company
Chenai Gondo
Senior Associate at McKinsey & Company + more
Dr. Chenai Gondo is a management consultant in the London office of McKinsey and Company, where she has served clients in the pharmaceutical, medical device, and the oil and gas sector. Her functional focus is on organizational transformations, mergers and acquisitions, business strategy and product development. She is uniquely positioned to understand organisations due to her background: prior to joining McKinsey, she spent 5 years as an academic researcher at ETH Zurich and the University of Pennsylvania. Her research was focused on the synthesis of organic compounds and peptides, and she also worked briefly as a researcher in the pharmaceutical industry. Chenai was born and raised in Harare, Zimbabwe and has since lived in Africa, North America and Europe. She speaks English, German and Shona. She is passionate about advancing the position and opportunities afforded to women and black people in business and leadership positions, and takes an active role in mentoring and networking with other women and people of color.
Someit Sidhu
Associate at McKinsey & Company + more
Associate at McKinsey & Company
Harriet Keane
Associate at McKinsey & Company + more
Associate at McKinsey & Company
Tracy Blois
Head of Business Development Operations at Amgen + more
Biochemist turned business development professional with broad interests in bridging communication between those in business and those in science. Committed to inspiring the next generation of scientists through involvement in scientific outreach and education. Specialties: Team leadership and taking initiative, Project management, Scientific communication, Biochemistry and Molecular Biology, Membrane protein folding.
Jeanne Bolger
Vice President Venture Investing at Johnson & Johnson + more
VP Investor with JJDC, Johnson & Johnson's Corporate Venture firm.. Based at the London Innovation Centre. Focus on investments in early to late stage pharmaceuticals / biotech companies in areas of strategic interest to Johnson & Johnson.